Treatment - Cancer Currents Blog
Cancer treatment related news, with context from leading experts. Includes articles on new therapies, treatment side effects, and important trends in treatment-related research.
- Take with Food: Study Tests Lowering Dose of Prostate Cancer Drug
In a small clinical trial, researchers compared the efficacy of a much lower dose of the cancer drug abiraterone (Zytiga) taken with a low-fat breakfast with a full dose taken on an empty stomach, as directed on the drug’s label.
- Cancer Immunotherapy Drug Simultaneously Targets Two Proteins that Block Immune Response
Two independent groups of researchers have fused a TGF-beta receptor to a monoclonal antibody that targets a checkpoint protein. The result is a single hybrid molecule called a Y-trap that blocks two pathways used by tumors to evade the immune system.
- NCI Launches New Resource for Specimens and Data from Cancer Clinical Trials
NCI has launched Navigator, a new resource for researchers interested in using specimens and clinical data collected from large cancer clinical trials.
- Many Men with Penile Cancer Do Not Get Recommended Treatments, Study Finds
An analysis of records from a national cancer treatment database has found that many men with penile cancer that has not spread beyond nearby lymph nodes did not undergo lymph node biopsy or receive chemotherapy, as recommended by widely used professional guidelines.
- Drug May Help Prevent Resistance to Toxin-Based Leukemia Therapy
A new study has identified a possible strategy for improving the efficacy of a toxin-based cancer treatment, moxetumomab pasudotox, in some patients with acute lymphoblastic leukemia (ALL).
- Targeted Therapy Larotrectinib Shows Promise in Early Trials, Regardless of Cancer Type
Initial results from a series of three small clinical trials of a targeted cancer therapy called larotrectinib suggest that it may be effective in patients—children and adults—with a wide variety of cancer types.
- Cabozantinib Approval Expands Initial Treatment Options for Advanced Kidney Cancer
The Food and Drug Administration has approved cabozantinib (Cabometyx®) as an initial treatment for patients with advanced renal cell carcinoma, the most common type of kidney cancer.
- Can Oxygen “Microbubbles” Make Radiation Therapy More Effective?
A new study in mice raises the possibility that using microscopic, oxygen-carrying bubbles may improve the effectiveness of radiation therapy in the treatment of breast cancer.
- Abiraterone Approved for Earlier Use in Men with Metastatic Prostate Cancer
The Food and Drug Administration (FDA) has expanded the approval of abiraterone (Zytiga®) for men with prostate cancer. The agency approved abiraterone, in combination with the steroid prednisone, for men with metastatic prostate cancer that is responsive to hormone-blocking treatments (also known as castration-sensitive) and is at high risk of progressing.
- For Rare Melanoma, Checkpoint Inhibitors May Hold Substantial Promise
A new study suggests that patients with a rare form of melanoma, called desmoplastic melanoma, may be particularly likely to benefit from treatments known as immune checkpoint inhibitors. An NCI-sponsored clinical trial is already testing one such drug in patients with this cancer.
- New Cancer Treatment Approach Targets Circadian Clock
Two compounds that target components of the circadian clock killed several types of cancer cells in the lab and slowed the growth of brain tumors in mice without harming healthy cells, a new study showed.
- Oncolytic Virus Therapy: Using Tumor-Targeting Viruses to Treat Cancer
A small but growing number of patients with cancer are being treated with oncolytic viruses, which infect and kill tumor cells. But research now suggests that these treatments also work against cancer by spurring an immune response.
- Gut Bacteria Influence Effectiveness of a Type of Immunotherapy
Using mouse models of cancer, researchers found that altering the gut microbiome could affect whether tumors responded to checkpoint inhibition.
- Study Identifies Potential Cause of Hearing Loss from Cisplatin
A new study has found the commonly used chemotherapy drug cisplatin is retained in the inner ear of mice and humans for long periods. The finding may explain why many patients treated with the drug develop hearing loss and could point toward potential ways to prevent it.
- Nilotinib Can Be Discontinued in Some Patients with Chronic Myelogenous Leukemia
On December 22, FDA approved an update to the label of nilotinib (Tasignia) that states that some patients with CML who are taking nilotinib and whose cancer has been in remission for an extended period can safely stop taking it.
- Drug Combination Improves Outlook for Some Patients with Chronic Lymphocytic Leukemia
Interim results from an ongoing clinical trial show that patients with relapsed or refractory chronic lymphocytic leukemia treated with rituximab plus venetoclax have longer progression-free survival compared with patients treated with chemotherapy.
- Unique Trial Aims to Decrease Early Deaths in Patients with Rare Leukemia
In a unique clinical trial, a group of oncologists with experience treating acute promyelocytic leukemia are making themselves available around the clock to help clinicians at hospitals across the country treat their APL patients.
- FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer
FDA has approved alectinib (Alecensa) as a first-line treatment option for patients with advanced non-small cell lung cancer that is ALK positive. Alectinib is the third ALK inhibitor to be approved in this setting.
- Expanding Smoking Cessation Services at NCI-designated Cancer Centers: An Interview with Dr. Glen Morgan
NCI’s Dr. Glen Morgan discusses NCI’s Cancer Center Cessation Initiative, including how and why this smoking cessation initiative was developed and its long-term goals.
- Alternate Driver of Treatment-Resistant Prostate Cancer Identified
Researchers have identified an emerging subtype of metastatic prostate cancer that is resistant to therapies that block hormones that fuel the disease.
- Study Identifies Potential Drug Combination for Ewing Sarcoma
From experiments in cells and mice, researchers have identified a two-drug combination that kills more Ewing sarcoma cells than either drug on its own. The study findings could help inform future clinical trials.
- Liquid Biopsy: Using DNA in Blood to Detect, Track, and Treat Cancer
Research studies show tests that analyze tumor DNA in blood, called liquid biopsies, may help detect cancer early, guide precision cancer treatment, and track treatment response.
- Study Tracks the Evolution of Treatment Resistance in Metastatic Breast Cancer
A new study suggests that the cells in treatment-resistant tumors in women with metastatic breast cancer share important characteristics that could potentially make tumors vulnerable to therapies that otherwise might not have been considered.
- Studies Identify Therapies That May Delay Melanoma Recurrence after Surgery
Two recent clinical trials have identified treatments that may delay cancer from returning in some patients with melanoma. Patients in both trials had advanced melanoma that was surgically removed, and each trial tested different forms of post-surgical, or adjuvant, therapy.
- Extensive Lymph Node Removal Doesn't Improve Survival in Some Women with Early-Stage Breast Cancer
Long-term results from a large clinical trial confirm that, for some women with early-stage breast cancer who have lumpectomy as their surgical treatment, a less extensive lymph node biopsy approach is sufficient.
- Timing and Sequence Critical for Immunotherapy Combination
When given at the same time, two immune checkpoint inhibitors were ineffective against breast cancer growth in mice, a new study found. The combination was more effective and safer if the two inhibitors were given in a specific sequence.
- Long-Term Nerve Damage Possible after Chemotherapy for Breast Cancer
Many women who receive taxane-based chemotherapy to treat breast cancer experience long-term nerve damage, or peripheral neuropathy, data from a large clinical trial show.
- Forgoing Conventional Cancer Treatments for Alternative Medicine Increases Risk of Death
In a large study, patients with nonmetastatic breast, lung, or colorectal cancer who chose alternative therapies had substantially worse survival than patients who received conventional cancer treatments.
- Bringing the Investigational Breast Cancer Drug Endoxifen from Bench to Bedside with NCI Support
Researchers recognized the potential of endoxifen as a treatment for breast cancer and, with NCI support, developed the compound into a drug now being tested in clinical trials.
- Modified Stem Cells Deliver Chemotherapy to Metastatic Tumors
Researchers have used modified stem cells to deliver a cancer drug selectively to metastatic breast cancer tumors in mice. The stem cells target metastatic tumors by homing in on the stiff environment that typically surrounds them.
- Heart Attack, Stroke Risk May Be Elevated Following Cancer Diagnosis
A diagnosis of cancer can come with an increased risk of a heart attack or stroke in the months after beginning treatment, a new study suggests. Within 6 months of a diagnosis, the risk of either event was more than twice that seen in people without cancer.
- In Melanoma, Personalized Treatment Vaccines Show Promise
Results of an early-phase trial showed that a treatment vaccine personalized to a specific patient’s cancer generated a robust immune response against the cancer and may have helped to prevent it from returning.
- Glioblastoma—Unraveling the Threads: A Q&A with Drs. Mark Gilbert and Terri Armstrong of the NIH Neuro-Oncology Branch
Progress against the brain cancer glioblastoma has been slow. Drs. Mark Gilbert and Terri Armstrong of NCI’s Neuro-Oncology Branch discuss why and what’s being done to change that.
- Cancer Researchers Report Progress in Studying Exceptional Responders
Researchers who study exceptional responders—patients who have dramatic and long-lasting responses to treatments for cancer that were not effective for most similar patients—met recently to discuss the state of the science in this emerging field.
- Extensive Lymph Node Surgery Does Not Increase Survival in Melanoma
A conservative approach to lymph node removal surgery may be best for people with melanoma that has spread from the skin to one or a small number of nearby lymph nodes, new results from a large international clinical trial suggest.
- FDA Expands Approval of Ceritinib for ALK-Positive Non-Small Cell Lung Cancer
The FDA has approved the targeted therapy ceritinib as an initial treatment for patients with lung cancer that has a mutation in the ALK gene.
- Abiraterone Improves Survival for Some Men with Hormone-Sensitive Prostate Cancer
In two large clinical trials, adding the hormone-blocking drug abiraterone to androgen-deprivation therapy (ADT) allowed men with metastatic hormone-sensitive prostate cancer to live longer than men who were treated with ADT alone.
- Trastuzumab Emtansine Improves Survival in Previously Treated Metastatic HER2-Positive Breast Cancer
Two clinical trials show that trastuzumab emtansine (T-DM1) improves survival compared with other standard treatments for patients with HER2-positive metastatic breast cancer that has progressed after treatment with other HER2-targeted drugs.
- CAR T Cells: Expanding into Multiple Myeloma
Results from two early-phase trials presented at the American Society of Clinical Oncology annual meeting suggest that an immunotherapy using genetically engineered immune cells may be effective in patients with advanced multiple myeloma.
- Less Chemotherapy May Be Best Choice for Some Patients with Colon Cancer, Study Shows
A shorter course of chemotherapy following surgery may be preferred to longer treatment for some patients with colon cancer, results of an international collaborative study suggest.
- Patients Who Choose No Intervention for Small Thyroid Cancers Report Lack of Support
Patients who choose not to pursue immediate biopsy or treatment for small, asymptomatic thyroid cancers, or suspected cancers, can experience a lack of support from doctors and loved ones, a new study shows.
- PARP Inhibitors May Be Effective in Brain, Other Cancers with IDH Mutations
Studies presented at the 2017 AACR annual meeting suggest that therapies which take advantage of the mutations in the IDH gene may be more effective than drugs that block it.
- Blinatumomab Extends Survival for Patients with Advanced ALL
Patients with previously treated acute lymphoblastic leukemia who received blinatumomab, which encourages the immune system to kill cancer cells, lived longer and experienced fewer side effects than patients given standard chemotherapy.
- Stem-Cell Based Tool May Help Measure Heart Toxicity of Cancer Drugs
Researchers have used adult stem cells to create a tool for ranking how toxic a group of cancer drugs, called tyrosine kinase inhibitors, are to human heart cells. Such a test could potentially identify toxic side effects earlier in the drug development process.
- Putting the Cancer Patient Front and Center: An Interview with NCI’s Dr. Paul Jacobsen
NCI’s Dr. Paul Jacobsen discusses NCI’s Healthcare Delivery Research Program and its role in advancing innovative research to improve the delivery of cancer care.
- Study Shows Platelets Can Deliver Immunotherapy, Reduce Tumor Regrowth
In experiments in mice, researchers show platelets linked to an immunotherapy drug can help eliminate residual cancer cells that remain after surgery. The engineered platelets may also prevent leftover cancer cells from spreading.
- Potential New Cancer Therapy Could Target Tumors Two Ways
A team of researchers has developed a potential new therapy that may work in two distinct ways to attack tumors, by directly killing cancer cells and immune cells that can suppress the anti-cancer immune response.
- Combination Therapy Improves Survival for Some Men with Recurrent Prostate Cancer
Long-term results from an NCI-sponsored clinical trial suggest that adding androgen deprivation therapy to radiation therapy can improve survival for some men with recurrent prostate cancer.
- Three-Drug Combination Extends Survival for Patients with Multiple Myeloma
A phase III clinical trial demonstrates that adding the drug bortezomib to a commonly used two-drug regimen extends survival in patients with newly diagnosed multiple myeloma.